Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models
Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our object...
Main Authors: | Andrey Ugolkov, Wenan Qiang, Gennadiy Bondarenko, Daniel Procissi, Irina Gaisina, C. David James, James Chandler, Alan Kozikowski, Hendra Gunosewoyo, Thomas O'Halloran, Jeffrey Raizer, Andrew P. Mazar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-08-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523317301067 |
Similar Items
-
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
by: Hiroo Kuroki, et al.
Published: (2019-12-01) -
Mechanistic studies on aziridinyl-benzoquinones and CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] in cultured tumour cells
by: Ben Rabha, Fatma Mohammed
Published: (2007) -
Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors
by: Gennadiy Bondarenko, et al.
Published: (2015-09-01) -
GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
by: Robin Park, et al.
Published: (2021-07-01) -
Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway
by: Lui Ng, et al.
Published: (2018-06-01)